JP2007537231A - ジペプチジルペプチダーゼivインヒビターとしてのプロリン誘導体およびそれらの使用 - Google Patents
ジペプチジルペプチダーゼivインヒビターとしてのプロリン誘導体およびそれらの使用 Download PDFInfo
- Publication number
- JP2007537231A JP2007537231A JP2007512552A JP2007512552A JP2007537231A JP 2007537231 A JP2007537231 A JP 2007537231A JP 2007512552 A JP2007512552 A JP 2007512552A JP 2007512552 A JP2007512552 A JP 2007512552A JP 2007537231 A JP2007537231 A JP 2007537231A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pyrrolidin
- prodrug
- methanone
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 title 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 title 1
- 150000003147 proline derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 188
- 229940002612 prodrug Drugs 0.000 claims abstract description 75
- 239000000651 prodrug Substances 0.000 claims abstract description 75
- 150000003839 salts Chemical class 0.000 claims abstract description 57
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims abstract description 5
- -1 —NR a R b Chemical group 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 44
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims description 31
- 206010012601 diabetes mellitus Diseases 0.000 claims description 25
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 21
- 239000012453 solvate Substances 0.000 claims description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 208000024891 symptom Diseases 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 15
- 206010020772 Hypertension Diseases 0.000 claims description 14
- 208000008589 Obesity Diseases 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 235000020824 obesity Nutrition 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 208000011580 syndromic disease Diseases 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 201000001320 Atherosclerosis Diseases 0.000 claims description 9
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 8
- 208000001132 Osteoporosis Diseases 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 239000003981 vehicle Substances 0.000 claims description 7
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 6
- 201000001421 hyperglycemia Diseases 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 208000002177 Cataract Diseases 0.000 claims description 5
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 5
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 5
- QWEWGXUTRTXFRF-KBPBESRZSA-N gosogliptin Chemical compound C1C(F)(F)CCN1C(=O)[C@H]1NC[C@@H](N2CCN(CC2)C=2N=CC=CN=2)C1 QWEWGXUTRTXFRF-KBPBESRZSA-N 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 231100000397 ulcer Toxicity 0.000 claims description 5
- 208000010444 Acidosis Diseases 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000010392 Bone Fractures Diseases 0.000 claims description 4
- 206010065687 Bone loss Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 206010061818 Disease progression Diseases 0.000 claims description 4
- 208000030814 Eating disease Diseases 0.000 claims description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
- 206010017076 Fracture Diseases 0.000 claims description 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 206010027417 Metabolic acidosis Diseases 0.000 claims description 4
- 206010049088 Osteopenia Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 4
- 201000007930 alcohol dependence Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 230000006806 disease prevention Effects 0.000 claims description 4
- 235000014632 disordered eating Nutrition 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 206010016256 fatigue Diseases 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 208000000509 infertility Diseases 0.000 claims description 4
- 230000036512 infertility Effects 0.000 claims description 4
- 231100000535 infertility Toxicity 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 206010022437 insomnia Diseases 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 206010013883 Dwarfism Diseases 0.000 claims description 3
- 206010056438 Growth hormone deficiency Diseases 0.000 claims description 3
- 206010049416 Short-bowel syndrome Diseases 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 3
- 125000004306 triazinyl group Chemical group 0.000 claims description 3
- 230000003313 weakening effect Effects 0.000 claims description 3
- JDQBLAQWJBHGNH-ZFWWWQNUSA-N (3,3-difluoropyrrolidin-1-yl)-[(2s,4s)-4-(2-ethoxy-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-6-yl)pyrrolidin-2-yl]methanone Chemical compound O=C([C@H]1NC[C@H](C1)N1CC2=CN=C(N=C2CC1)OCC)N1CCC(F)(F)C1 JDQBLAQWJBHGNH-ZFWWWQNUSA-N 0.000 claims description 2
- JOEYRUNHVDLBCM-GJZGRUSLSA-N (3,3-difluoropyrrolidin-1-yl)-[(2s,4s)-4-[4-(4-methylpyrimidin-2-yl)piperazin-1-yl]pyrrolidin-2-yl]methanone Chemical compound CC1=CC=NC(N2CCN(CC2)[C@H]2C[C@H](NC2)C(=O)N2CC(F)(F)CC2)=N1 JOEYRUNHVDLBCM-GJZGRUSLSA-N 0.000 claims description 2
- YQVZUCGTBYZKJR-KBPBESRZSA-N (3,3-difluoropyrrolidin-1-yl)-[(2s,4s)-4-[4-([1,3]oxazolo[4,5-c]pyridin-2-yl)piperazin-1-yl]pyrrolidin-2-yl]methanone Chemical compound C1C(F)(F)CCN1C(=O)[C@H]1NC[C@@H](N2CCN(CC2)C=2OC3=CC=NC=C3N=2)C1 YQVZUCGTBYZKJR-KBPBESRZSA-N 0.000 claims description 2
- UJYFJSDMPVLXQF-AAEUAGOBSA-N (3-fluoroazetidin-1-yl)-[(2s,4s)-4-[2-(trifluoromethyl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-6-yl]pyrrolidin-2-yl]methanone Chemical compound C1C(F)CN1C(=O)[C@H]1NC[C@@H](N2CC3=CN=C(N=C3CC2)C(F)(F)F)C1 UJYFJSDMPVLXQF-AAEUAGOBSA-N 0.000 claims description 2
- SVMVVQFUWVFMQG-YJBOKZPZSA-N (3-fluoroazetidin-1-yl)-[(2s,4s)-4-[4-[2-(trifluoromethyl)quinolin-4-yl]piperazin-1-yl]pyrrolidin-2-yl]methanone Chemical compound C1C(F)CN1C(=O)[C@H]1NC[C@@H](N2CCN(CC2)C=2C3=CC=CC=C3N=C(C=2)C(F)(F)F)C1 SVMVVQFUWVFMQG-YJBOKZPZSA-N 0.000 claims description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- FEWIVIWLJAYUNJ-HOTGVXAUSA-N 2-[4-[(3s,5s)-5-(3-fluoroazetidine-1-carbonyl)pyrrolidin-3-yl]piperazin-1-yl]pyridine-3-carbonitrile Chemical compound C1C(F)CN1C(=O)[C@H]1NC[C@@H](N2CCN(CC2)C=2C(=CC=CN=2)C#N)C1 FEWIVIWLJAYUNJ-HOTGVXAUSA-N 0.000 claims description 2
- JORHXWUOXGUKMM-ULQDDVLXSA-N 2-[4-[(3s,5s)-5-[(3s)-3-fluoropyrrolidine-1-carbonyl]pyrrolidin-3-yl]piperazin-1-yl]pyridine-3-carbonitrile Chemical compound C1[C@@H](F)CCN1C(=O)[C@H]1NC[C@@H](N2CCN(CC2)C=2C(=CC=CN=2)C#N)C1 JORHXWUOXGUKMM-ULQDDVLXSA-N 0.000 claims description 2
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
- 230000004899 motility Effects 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 51
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract description 4
- 208000033679 diabetic kidney disease Diseases 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 2
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 abstract 1
- 201000009101 diabetic angiopathy Diseases 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 117
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 59
- 239000000243 solution Substances 0.000 description 47
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 37
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 29
- 239000000047 product Substances 0.000 description 29
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 19
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 19
- 235000019341 magnesium sulphate Nutrition 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 19
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 19
- 239000003112 inhibitor Substances 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 239000012267 brine Substances 0.000 description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 239000008103 glucose Substances 0.000 description 16
- 230000008569 process Effects 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 14
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 13
- 239000003472 antidiabetic agent Substances 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 230000036470 plasma concentration Effects 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 229960002429 proline Drugs 0.000 description 8
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 8
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 150000001412 amines Chemical group 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 6
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 6
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 102100040918 Pro-glucagon Human genes 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 5
- CKYGSXRXTIKGAJ-ZETCQYMHSA-N Boc-L-Pro(4-oxo) Chemical compound CC(C)(C)OC(=O)N1CC(=O)C[C@H]1C(O)=O CKYGSXRXTIKGAJ-ZETCQYMHSA-N 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- 229940125708 antidiabetic agent Drugs 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000012442 inert solvent Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000001030 gas--liquid chromatography Methods 0.000 description 4
- 150000003840 hydrochlorides Chemical class 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 238000004460 liquid liquid chromatography Methods 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 3
- YYVPZQADFREIFR-UHFFFAOYSA-N 3,3-difluoropyrrolidine;hydrochloride Chemical compound [Cl-].FC1(F)CC[NH2+]C1 YYVPZQADFREIFR-UHFFFAOYSA-N 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 229940127003 anti-diabetic drug Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 150000004283 biguanides Chemical class 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 238000007410 oral glucose tolerance test Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 description 2
- BENKAPCDIOILGV-RQJHMYQMSA-N (2s,4r)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(O)=O BENKAPCDIOILGV-RQJHMYQMSA-N 0.000 description 2
- JDUYOMPVOXGHIR-HKTIBRIUSA-N (3r,4s)-3,4-difluoropyrrolidine;hydrochloride Chemical compound Cl.F[C@H]1CNC[C@H]1F JDUYOMPVOXGHIR-HKTIBRIUSA-N 0.000 description 2
- MRBFGEHILMYPTF-UHFFFAOYSA-N 1-(2-Pyrimidyl)piperazine Chemical compound C1CNCCN1C1=NC=CC=N1 MRBFGEHILMYPTF-UHFFFAOYSA-N 0.000 description 2
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 0 C*(C[C@@](C)(C1(*)*)C2=C*CC*CC(CO*=C)*C2)C1C(*1CC1)=O Chemical compound C*(C[C@@](C)(C1(*)*)C2=C*CC*CC(CO*=C)*C2)C1C(*1CC1)=O 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 229940121931 Gluconeogenesis inhibitor Drugs 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 2
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 2
- 238000010268 HPLC based assay Methods 0.000 description 2
- 229940122199 Insulin secretagogue Drugs 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 2
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 239000012042 active reagent Substances 0.000 description 2
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 239000003288 aldose reductase inhibitor Substances 0.000 description 2
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000005206 alkoxycarbonyloxymethyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 230000003243 anti-lipolytic effect Effects 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 108010054812 diprotin A Proteins 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- QMMMCTXNYMSXLI-UHFFFAOYSA-N fast blue B Chemical compound C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 QMMMCTXNYMSXLI-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 239000003324 growth hormone secretagogue Substances 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 150000002462 imidazolines Chemical class 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- VAUAJWPEBZXSES-JTQLQIEISA-N tert-butyl (2s)-2-(3,3-difluoropyrrolidine-1-carbonyl)-4-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)C[C@H]1C(=O)N1CC(F)(F)CC1 VAUAJWPEBZXSES-JTQLQIEISA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 2
- IYLMARVOIYCGET-RSAXXLAASA-N (2S)-1-(2-aminoacetyl)-N-(4-methoxynaphthalen-2-yl)pyrrolidine-2-carboxamide hydrochloride Chemical compound Cl.C=1C2=CC=CC=C2C(OC)=CC=1NC(=O)[C@@H]1CCCN1C(=O)CN IYLMARVOIYCGET-RSAXXLAASA-N 0.000 description 1
- BOGMTOHWIVLVJE-WCCKRBBISA-N (2s)-4,4-difluoropyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.FC1(F)CN[C@H](C#N)C1 BOGMTOHWIVLVJE-WCCKRBBISA-N 0.000 description 1
- YGWZXQOYEBWUTH-BQBZGAKWSA-N (2s,4s)-4-fluoro-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1C[C@@H](F)C[C@H]1C(O)=O YGWZXQOYEBWUTH-BQBZGAKWSA-N 0.000 description 1
- OLZBUMFLINUMEV-FHAQVOQBSA-N (2s,4s)-4-fluoropyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.F[C@@H]1CN[C@H](C#N)C1 OLZBUMFLINUMEV-FHAQVOQBSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- LENYOXXELREKGZ-WCCKRBBISA-N (3s)-3-fluoropyrrolidin-1-ium;chloride Chemical compound Cl.F[C@H]1CCNC1 LENYOXXELREKGZ-WCCKRBBISA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000005845 (C2-C12)alkanoyloxymethyl group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- FHUDAMLDXFJHJE-UHFFFAOYSA-N 1,1,1-trifluoropropan-2-one Chemical compound CC(=O)C(F)(F)F FHUDAMLDXFJHJE-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- KKIMDKMETPPURN-UHFFFAOYSA-N 1-(3-(trifluoromethyl)phenyl)piperazine Chemical compound FC(F)(F)C1=CC=CC(N2CCNCC2)=C1 KKIMDKMETPPURN-UHFFFAOYSA-N 0.000 description 1
- 125000005846 1-(alkanoyloxy)ethyl group Chemical group 0.000 description 1
- 125000005848 1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- YMXAILYGDPCVFW-UHFFFAOYSA-N 1-benzhydryl-3-fluoroazetidine;hydrochloride Chemical compound Cl.C1C(F)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 YMXAILYGDPCVFW-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- UJIBOGAQJRDRES-UHFFFAOYSA-N 1h-pyridin-2-one Chemical compound OC1=CC=CC=N1.O=C1C=CC=CN1 UJIBOGAQJRDRES-UHFFFAOYSA-N 0.000 description 1
- NJYBIFYEWYWYAN-UHFFFAOYSA-N 2,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1F NJYBIFYEWYWYAN-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 1
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- KPTMFLKIYHWQPB-UHFFFAOYSA-N 3,3,4,4-tetrafluoropyrrolidine;hydrochloride Chemical compound Cl.FC1(F)CNCC1(F)F KPTMFLKIYHWQPB-UHFFFAOYSA-N 0.000 description 1
- CDBAEFXTCRKJPZ-UHFFFAOYSA-N 3,3-difluoroazetidine;hydron;chloride Chemical compound Cl.FC1(F)CNC1 CDBAEFXTCRKJPZ-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- PXFUWRWCKSLCLS-UHFFFAOYSA-N 3-fluoroazetidine;hydron;chloride Chemical compound Cl.FC1CNC1 PXFUWRWCKSLCLS-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 1
- OHEBHIBORTYCPU-UHFFFAOYSA-N C=NCCN[N](C1CC1)(=C)=C Chemical compound C=NCCN[N](C1CC1)(=C)=C OHEBHIBORTYCPU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ZYEBSDIDMOWTTK-UHFFFAOYSA-N Cl.Cl.FC1(CN(CC1)C=O)F Chemical compound Cl.Cl.FC1(CN(CC1)C=O)F ZYEBSDIDMOWTTK-UHFFFAOYSA-N 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910017976 MgO 4 Inorganic materials 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 125000005855 N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl group Chemical group 0.000 description 1
- 125000005850 N-(alkoxycarbonyl)aminomethyl group Chemical group 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 125000005861 N—(C1-C6)alkoxycarbonylaminomethyl group Chemical group 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- CGVGUDBPFSKJPA-IUCAKERBSA-N O=C1N(C(CC1)=O)OC(=O)N1[C@@H](C[C@@H](C1)F)C(=O)OC(C)(C)C Chemical compound O=C1N(C(CC1)=O)OC(=O)N1[C@@H](C[C@@H](C1)F)C(=O)OC(C)(C)C CGVGUDBPFSKJPA-IUCAKERBSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100029909 Peptide YY Human genes 0.000 description 1
- 108010088847 Peptide YY Proteins 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- QYTDEUPAUMOIOP-UHFFFAOYSA-N TEMPO Chemical group CC1(C)CCCC(C)(C)N1[O] QYTDEUPAUMOIOP-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- HZDLBJMCHHWVML-HOCLYGCPSA-N [(2s,4s)-4-(2-cyclopropyl-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-6-yl)pyrrolidin-2-yl]-(3-fluoroazetidin-1-yl)methanone Chemical compound C1C(F)CN1C(=O)[C@H]1NC[C@@H](N2CC3=CN=C(N=C3CC2)C2CC2)C1 HZDLBJMCHHWVML-HOCLYGCPSA-N 0.000 description 1
- AOZSICZASFBARD-NJHZPMQHSA-N [(2s,4s)-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrrolidin-2-yl]-(3,3,4,4-tetrafluoropyrrolidin-1-yl)methanone;dihydrochloride Chemical compound Cl.Cl.C1C(F)(F)C(F)(F)CN1C(=O)[C@H]1NC[C@@H](N2CCN(CC2)C=2N=CC=CN=2)C1 AOZSICZASFBARD-NJHZPMQHSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 235000021229 appetite regulation Nutrition 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- NCRXQCGIQTUUJZ-PHIMTYICSA-N benzyl (3r,4s)-3,4-difluoropyrrolidine-1-carboxylate Chemical compound C1[C@@H](F)[C@@H](F)CN1C(=O)OCC1=CC=CC=C1 NCRXQCGIQTUUJZ-PHIMTYICSA-N 0.000 description 1
- UJNOAYOEDMPPFA-UHFFFAOYSA-N benzyl 2,5-dihydropyrrole-1-carboxylate 2,5-dihydro-1H-pyrrole Chemical compound N1CC=CC1.C(C1=CC=CC=C1)OC(=O)N1CC=CC1 UJNOAYOEDMPPFA-UHFFFAOYSA-N 0.000 description 1
- FKICDDSBRVLUCQ-UHFFFAOYSA-N benzyl 3-fluoro-4-hydroxypyrrolidine-1-carboxylate Chemical compound C1C(F)C(O)CN1C(=O)OCC1=CC=CC=C1 FKICDDSBRVLUCQ-UHFFFAOYSA-N 0.000 description 1
- ZOGDLRYHUKGYDJ-SFTDATJTSA-N benzyl 4-[(3s,5s)-5-(3,3-difluoropyrrolidine-1-carbonyl)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]piperazine-1-carboxylate Chemical compound O=C([C@@H]1C[C@@H](CN1C(=O)OC(C)(C)C)N1CCN(CC1)C(=O)OCC=1C=CC=CC=1)N1CCC(F)(F)C1 ZOGDLRYHUKGYDJ-SFTDATJTSA-N 0.000 description 1
- FZDACFZWWMAUBO-UHFFFAOYSA-N benzyl 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1C2OC2CN1C(=O)OCC1=CC=CC=C1 FZDACFZWWMAUBO-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- CTOUWUYDDUSBQE-UHFFFAOYSA-N benzyl piperazine-1-carboxylate Chemical compound C1CNCCN1C(=O)OCC1=CC=CC=C1 CTOUWUYDDUSBQE-UHFFFAOYSA-N 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- MOOAHMCRPCTRLV-UHFFFAOYSA-N boron sodium Chemical compound [B].[Na] MOOAHMCRPCTRLV-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000005854 carbamoyl-(C1-C2)alkyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229940117975 chromium trioxide Drugs 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- UVJHQYIOXKWHFD-UHFFFAOYSA-N cyclohexa-1,4-diene Chemical compound C1C=CCC=C1 UVJHQYIOXKWHFD-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000005852 di-N,N—(C1-C2)alkylamino(C2-C3)alkyl group Chemical group 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
- VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- JZBWUTVDIDNCMW-UHFFFAOYSA-L dipotassium;oxido sulfate Chemical compound [K+].[K+].[O-]OS([O-])(=O)=O JZBWUTVDIDNCMW-UHFFFAOYSA-L 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000011953 free-radical catalyst Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002373 hemiacetals Chemical group 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000005858 morpholino(C2-C3)alkyl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 125000005856 piperidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 208000003068 pituitary dwarfism Diseases 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- YMURVSOXVWNMCE-UHFFFAOYSA-N pyrrolidine-1-carbaldehyde dihydrochloride Chemical compound Cl.Cl.N1(CCCC1)C=O YMURVSOXVWNMCE-UHFFFAOYSA-N 0.000 description 1
- 125000005857 pyrrolidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- QXNXVWNYCKUANQ-UHFFFAOYSA-N spiro[indene-1,4'-piperidine] Chemical compound C1CNCCC21C1=CC=CC=C1C=C2 QXNXVWNYCKUANQ-UHFFFAOYSA-N 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- UXCIUYGWTWMFOT-DIQYCMFJSA-N tert-butyl (2S)-2-(3,3-difluoropyrrolidine-1-carbonyl)-4-oxopyrrolidine-1-carboxylate (2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]-4-oxopyrrolidine-2-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)N1[C@@H](CC(C1)=O)C(=O)O.C(C)(C)(C)OC(=O)N1[C@@H](CC(C1)=O)C(=O)N1CC(CC1)(F)F UXCIUYGWTWMFOT-DIQYCMFJSA-N 0.000 description 1
- LRUMTRQFZGRTDT-VIFPVBQESA-N tert-butyl (2s)-2-(3,3-difluoroazetidine-1-carbonyl)-4-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)C[C@H]1C(=O)N1CC(F)(F)C1 LRUMTRQFZGRTDT-VIFPVBQESA-N 0.000 description 1
- VWASJAYYVZMSDA-JTQLQIEISA-N tert-butyl (2s)-2-(3-fluoroazetidine-1-carbonyl)-4-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)C[C@H]1C(=O)N1CC(F)C1 VWASJAYYVZMSDA-JTQLQIEISA-N 0.000 description 1
- MVTKOAJSUWWMOO-ONGXEEELSA-N tert-butyl (2s)-2-[(3s)-3-fluoropyrrolidine-1-carbonyl]-4-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)C[C@H]1C(=O)N1C[C@@H](F)CC1 MVTKOAJSUWWMOO-ONGXEEELSA-N 0.000 description 1
- VMPHVWQOQMBPNP-ZJUUUORDSA-N tert-butyl (2s,4r)-2-(3,3-difluoropyrrolidine-1-carbonyl)-4-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(=O)N1CC(F)(F)CC1 VMPHVWQOQMBPNP-ZJUUUORDSA-N 0.000 description 1
- NGOWROOEDIAESU-IRXDYDNUSA-N tert-butyl (2s,4s)-2-(3,3-difluoropyrrolidine-1-carbonyl)-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrrolidine-1-carboxylate Chemical compound O=C([C@@H]1C[C@@H](CN1C(=O)OC(C)(C)C)N1CCN(CC1)C=1N=CC=CN=1)N1CCC(F)(F)C1 NGOWROOEDIAESU-IRXDYDNUSA-N 0.000 description 1
- UFNHUZXTWXLHEO-PMACEKPBSA-N tert-butyl (2s,4s)-2-(3,3-difluoropyrrolidine-1-carbonyl)-4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]pyrrolidine-1-carboxylate Chemical compound O=C([C@@H]1C[C@@H](CN1C(=O)OC(C)(C)C)N1CCN(CC1)C=1C=C(C=CC=1)C(F)(F)F)N1CCC(F)(F)C1 UFNHUZXTWXLHEO-PMACEKPBSA-N 0.000 description 1
- NEYBZYHUJLJPLN-KBPBESRZSA-N tert-butyl (2s,4s)-2-(3,3-difluoropyrrolidine-1-carbonyl)-4-piperazin-1-ylpyrrolidine-1-carboxylate Chemical compound O=C([C@@H]1C[C@@H](CN1C(=O)OC(C)(C)C)N1CCNCC1)N1CCC(F)(F)C1 NEYBZYHUJLJPLN-KBPBESRZSA-N 0.000 description 1
- SQGNCVVKJIZGLC-BQBZGAKWSA-N tert-butyl (2s,4s)-2-carbamoyl-4-fluoropyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@@H](F)C[C@H]1C(N)=O SQGNCVVKJIZGLC-BQBZGAKWSA-N 0.000 description 1
- QAKRZINKSNCLEV-YUMQZZPRSA-N tert-butyl (2s,4s)-2-cyano-4-fluoropyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@@H](F)C[C@H]1C#N QAKRZINKSNCLEV-YUMQZZPRSA-N 0.000 description 1
- HHDJOGSRJHUGHK-HOTGVXAUSA-N tert-butyl (2s,4s)-4-(4-pyrimidin-2-ylpiperazin-1-yl)-2-(3,3,4,4-tetrafluoropyrrolidine-1-carbonyl)pyrrolidine-1-carboxylate Chemical compound O=C([C@@H]1C[C@@H](CN1C(=O)OC(C)(C)C)N1CCN(CC1)C=1N=CC=CN=1)N1CC(F)(F)C(F)(F)C1 HHDJOGSRJHUGHK-HOTGVXAUSA-N 0.000 description 1
- VDUMPXDJOXFRIA-PXNSSMCTSA-N tert-butyl (2s,4s)-4-[4-(2,4-difluorobenzoyl)piperazin-1-yl]-2-(3,3-difluoropyrrolidine-1-carbonyl)pyrrolidine-1-carboxylate Chemical compound O=C([C@@H]1C[C@@H](CN1C(=O)OC(C)(C)C)N1CCN(CC1)C(=O)C=1C(=CC(F)=CC=1)F)N1CCC(F)(F)C1 VDUMPXDJOXFRIA-PXNSSMCTSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 150000003681 vanadium Chemical class 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 125000005863 α-amino(C1-C4)alkanoyl group Chemical group 0.000 description 1
- 125000005853 β-dimethylaminoethyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
Abstract
Description
R1が、−(C1−C6)アルキル、−(C1−C6)アルコキシ、−(Cl−C6)アリールアルキル、−NRaRb、ヒドロキシ、シアノ、アリールまたはヘテロアリールであり、ここで、前記−(C1−C6)アルキル、前記アリールまたは前記ヘテロアリールは、場合によって、1〜3個の以下:−COOH、−C(O)(C1−C6)アルコキシ、−C(O)(C1−C6)アルキル、−C(O)NRaRb、シアノ、ハロゲン、ニトロ、トリフルオロメチル、−(C1−C6)アルキル、−(C1−C6)アルコキシ、−(C3−C6)シクロアルキルまたはフェニルで独立して置換され、ここで、RaおよびRbが独立して、水素、−(C1−C6)アルキル、アリールまたはヘテロアリールであるか、またはRaおよびRbが、それらが結合する窒素原子と一緒になって、4〜6員の複素環式環を形成し、ここで前記環は、場合によって、さらに1〜2個の窒素、酸素または硫黄環ヘテロ原子を組み込み;
R2およびR3が、独立して、水素、ハロゲン、−(C1−C6)アルキルまたは−(C3−C8)シクロアルキルであり;
Qが、共有結合、−C(O)−または−SO2−であり;
HETが、場合によって(A)1〜6個のハロゲン原子、−(C1−C6)アルコキシ、シアノ、ハロゲン、ヒドロキシもしくは−NRaRbで場合によって置換されている1〜4個の−(C1−C6)アルキルまたは(B)1〜6個のハロゲン原子、−(C1−C6)アルコキシ、シアノ、ハロゲン、ヒドロキシもしくは−NRaRbで場合によって置換されている−(C1−C6)アリールアルキルで置換されている、ヘテロシクロアルキル環部分であり;
nが0または1であり;
Xが−CH2−、−CHF−または−CF2−であり、かつYが−CH2−、−CHF−または−CF2−であり(但しnが1である場合、XおよびYの両方が−CH2−でなく、
そしてnが0である場合、Xが−CH2−である);そして
Zが水素またはシアノである。
語句「薬学的に受容可能な」とは、設計された担体、ビヒクル、希釈剤、賦形剤および/または塩が、一般的に、製剤を含む他の成分と化学的および/または物理的に適合し、そしてそれらの受容体と生理的に適合することを表す。
R1が、独立して、1〜3個のシアノ、ハロゲン、ニトロ、トリフルオロメチル、−(Cl−C6)アルキル、−(Cl−C6)アルコキシ、−(C3−C6)シクロアルキルまたはフェニルで場合によって置換されているアリールまたはヘテロアリールであり;
R2が、−Hまたは−(C1−C6)アルキルであり;
R3が、−H−(C1−C6)アルキルであり;そして
HETが、アゼチジニル、ピペラジニル、ピペリジニル、ピロリジニル、5,6−ジヒドロ−8H−イミダゾ[1,2−a]ピラジン−7−イル、5,6−ジヒドロ−8H−[1,2,4]トリアゾロ[4,3−a]ピラジン−7−イルまたは7,8−ジヒドロ−5H−ピリド[4,3−a]ピリミジン−6−イルである。
R1が、ベンゾイソチアゾリル、ベンゾイソオキサゾリル、イソチアゾリル、イソオキサゾリル、オキサゾロピリジル、ピラジニル、ピリジニル、ピリミジニル、キノリニル、キノキサリニル、チアジアゾリル、トリアジニルまたは1,1−ジオキソ−1H−1,2−ベンゾイソチアゾリルである。
((2S,4S)−4−(3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)ピロリジン−2−イル)−(3,3−ジフルオロピロリジン−1−イル)−メタノン、
(3,3−ジフルオロピロリジン−1−イル)−((2S,4S)−4−(4−(オキサゾロ[5,4−b]ピリジン−2−イル)ピペラジン−1−イル)ピロリジン−2−イル)−メタノン、
(3,3−ジフルオロピロリジン−1−イル)−((2S,4S)−4−(4−(4−メチルピリミジン−2−イル)ピペラジン−1−イル)ピロリジン−2−イル)−メタノン、
((2S,4S)−4−(2−(トリフルオロメチル)−7,8−ジヒドロピリド[4,3−d]ピリミジン−6(5H)−イル)ピロリジン−2−イル)−(3,3−ジフルオロピロリジン−1−イル)−メタノン、
((S)−3−フルオロ−ピロリジン−1−イル)−{(2S,4S)−4−[4−(3−トリフルオロメチル−ピリジン−2−イル)−ピペラジン−1−イル]−ピロリジン−2−イル}−メタノン、
((S)−3−フルオロ−ピロリジン−1−イル)−[(2S,4S)−4−(2−トリフルオロメチル−7,8−ジヒドロ−5H−ピリド[4,3−d]ピリミジン−6−イル)−ピロリジン−2−イル]−メタノン、
(3,3−ジフルオロ−ピロリジン−1−イル)−[(2S,4S)−4−(4−オキサゾロ[4,5−c]ピリジン−2−イル−ピペラジン−1−イル)−ピロリジン−2−イル]−メタノン、
[(2S,4S)−4−(2−シクロプロピル−7,8−ジヒドロ−5H−ピリド[4,3−d]ピリミジン−6−イル)−ピロリジン−2−イル]−(3−フルオロ−アゼチジン−1−イル)−メタノン、
2−{4−[(3S,5S)−5−(3−フルオロ−アゼチジン−1−カルボニル)−ピロリジン−3−イル]−ピペラジン−1−イル}−ニコチノニトリル、
((S)−3−フルオロ−ピロリジン−1−イル)−[(2S,4S)−4−(4−オキサゾロ[5,4−b]ピリジン−2−イル−ピペラジン−1−イル)−ピロリジン−2−イル]−メタノン、
(3−フルオロ−アゼチジン−1−イル)−[(2S,4S)−4−(2−トリフルオロメチル−7,8−ジヒドロ−5H−ピリド[4,3−d]ピリミジン−6−イル)−ピロリジン−2−イル]−メタノン、
2−{4−[(3S,5S)−5−((S)−3−フルオロ−ピロリジン−1−カルボニル)−ピロリジン−3−イル]−ピペラジン−1−イル}−ニコチノニトリル、
(3−フルオロ−アゼチジン−1−イル)−{(2S,4S)−4−[4−(2−トリフルオロメチル−キノリン−4−イル)−ピペラジン−1−イル]−ピロリジン−2−イル}−メタノン、
((3R*,4S*)−3,4−ジフルオロ−ピロリジン−1−イル)−[(2S,4S)−4−(2−トリフルオロメチル−7,8−ジヒドロ−5H−ピリド[4,3−d]ピリミジン−6−イル)−ピロリジン−2−イル]−メタノンおよび
((3R*,4S*)−3,4−ジフルオロ−ピロリジン−1−イル)−[(2S,4S)−4−(4−オキサゾロ[5,4−b]ピリジン−2−イル−ピペラジン−1−イル)−ピロリジン−2−イル]−メタノン。
本発明のヒドロキシピリジンが2つの分離した互変異性体、例えば、
ほかに記載されない限り、全ての反応物は市販されていた。
フラッシュクロマトグラフィーを、W.C.Still et al.のJ.Org.Chem.1978,43,2923によって記載される方法に従って行った。
本発明の化合物および中間体は、一般的にNomenclature of Organic ChemistryおよびCAS IndexルールのIUPAC(International Union for Pure and Applied Chemistry)勧告に従って命名された。
(2S)−2−[(3,3−ジフルオロピロリジン−1−イル)カルボニル]−4−オキソピロリジン−1−カルボン酸tert−ブチルエステル
工程1 (2S,4R)−2−[(3,3−ジフルオロピロリジン−1−イル)カルボニル]−4−ヒドロキシピロリジン−1−カルボン酸tert−ブチルエステル
TEA(0.77mL、5.5mmol)を、3,3−ジフルオロピロリジン塩酸塩(0.79g、5.5mmol;Synlett,55(1995))のジクロロメタン懸濁液(10mL)に添加した。5分後、(4R)−1−(tert−ブトキシカルボニル)−4−ヒドロキシ−L−プロリン(1.16g、5mmol)、HOBt(0.74g、5.5mmol)およびEDC(1.05g、5.5mmol)を添加した。反応系を一晩撹拌した後、混合物を飽和重炭酸ナトリウムおよびブラインで連続して洗浄し、硫酸マグネシウムで乾燥させ、濾過し、そして濃縮した。残留物をクロマトグラフィー(Biotage(R)Flash 40S(A Dynax Corp.;Charlottesville,VA)、9:1ジクロロメタン:メタノール)によって精製し、淡いピンク色の発泡体(1.07g)を得た。水層のジクロロメタン抽出を繰り返してさらなる生成物(0.26g)を得、全体で1.33g(83%)の収量を得た。MS m/z 321(MH+)。
ジクロロメタン(3mL)中のDMSO(0.57mL、8mmol)を−65℃の塩化オキサリル(0.38mL、4.4mmol)のジクロロメタン溶液(10mL)に滴下した。5分後、工程1の生成物(1.28g、4mmol)のジクロロメタン溶液(20mL)を添加した。15分後、TEA(2.79mL、20mmol)を添加した。反応混合物をRTまで温めた。2時間後、混合物を氷上に注いだ。有機層を分離し、10% NaHCO3溶液およびブラインで連続して洗浄し、乾燥させ(MgO4)、そして濃縮した。残留物をクロマトグラフィー(Biotage(R)Flash 40S,95:5ジクロロメタン:MeOH)によって精製し、表題化合物(765mg、60%)を得た。MS m/z 319(MH+)。
(2S)−2−{[(3R*−4S*)−3,4−ジフルオロピロリジン−1−イル]カルボニル}−4−オキソピロリジン−1−カルボン酸tert−ブチルエステル
工程1 (2S,4R)−2−{[(3R*,4S*)−3,4ジフルオロピロリジン−1−イル]カルボニル}−4−ヒドロキシピロリジン−1−カルボン酸tert−ブチルエステル
製造1の工程1に記載されるのと類似の様式で、(4R)−1−(tert−ブトキシカルボニル)−4−ヒドロキシ−L−プロリン(2.31g、10mmol)を、(3R,4S)−rel−3,4−ジフルオロピロリジン塩酸塩(1.44g、10mmol、製造4)とカップリングし、オフホワイトの発泡体として表題化合物(2.15g、67%)を得た。MS m/z 321(MH+)。
工程2
製造1の工程2に記載されるのと類似の様式で、工程1の生成物(1.97g、6.15mmol)を酸化し、淡黄色固体として表題化合物(0.74g、38%)を得た。MS m/z 319(MH+)。
(4S)−1−(tert−ブトキシカルボニル)−4−(4−ピリミジン−2−イルピペラジン−1−イル)−L−プロリン
1−(tert−ブトキシカルボニル)−4−オキソ−L−プロリン(1.0g、4.4mmol)、2−ピペラジン−1−イルピリミジン(0.73g、4.4mmol)および酢酸(275μL、4.6mmol)を無水1,2−ジクロロエタン(20mL)に溶解し、そしてトリアセトキシ水素化ホウ素ナトリウム(1.85g、8.7mmol)を添加した。RTにて24時間撹拌した後、反応混合物を飽和NaHCO3でクエンチした。固体NaHCO3および濃HClの添加によってpHをpH7に調節し、混合物をジクロロメタンで抽出し、MgSO4で乾燥させ、濾過し、そして濃縮し、粗物質(1.0、61%)を得、これはさらに使用するために十分に純粋であった。MS m/z 378(MH+)。
(3R,4S)−rel−3,4−ジフルオロ−ピロリジン塩酸塩
工程1 2,5−ジヒドロ−ピロール−1−カルボン酸ベンジルエステル
3−ピロリン(10g、0.145mol)をトルエン(100mL)中の重炭酸ナトリウム(14g、0.17mol)のスラリーに添加した。混合物を0℃に冷却し、そしてクロロギ酸ベンジル(23mL、0.16mol)を滴下した。一晩撹拌した後、溶液をジクロロメタンで希釈し、冷水およびブラインで洗浄し、硫酸マグネシウムで乾燥させ、そして黄白色油状物になるまで濃縮し、真空で蒸留した。Bp 119〜126℃(0.32mm)。
工程1の表題化合物(3.0g、15mmol)を、エチレンジアミン四酢酸、ジナトリウム塩二水和物(11mg、0.03mmol)を含有するアセトニトリル(100mL)および水(70mL)の混合物に溶解した。溶液を0℃に冷却し、そして1,1,1−トリフルオロアセトン(14.5mL、160mmol)を10分かけて添加した。重炭酸ナトリウムを添加することによってpHを7に維持しながら、ペルオキソ一硫酸カリウム(45g、74mmol)を数滴ずつ40分かけて添加した。混合物を0℃にて1.5時間撹拌し、次いで水に注ぎ、そしてジクロロメタンで抽出した。合わせた抽出物を硫酸マグネシウムで乾燥させ、そして無色の油状物になるまで濃縮した(3.45g、100%)。
TEAトリヒドロフルオリド(1.95mL、12mmol)と工程2の表題化合物(2.62g、12mmol)の混合物を155℃にて3時間加熱し、冷却し、そして水とジクロロメタンとの間で分配した。水層を再びジクロロメタンで抽出し、そして合わせた有機抽出物をブラインで洗浄し、硫酸マグネシウムで乾燥させ、そして濃縮した。残留物をフラッシュクロマトグラフィー(ジクロロメタン中1%メタノール)によって精製し、青白い油状物として表題化合物(1.14g、40%)を得た。
工程3の表題化合物のジクロロメタン溶液(15mL)を−50℃に冷却し、そして[ビス(2−メトキシエチル)アミノ]三フッ化硫黄(1.3mL、6.9mmol)を添加した。溶液を室温まで18時間かけて温め、次いで水とEtOAcとの間で分配した。水層を再びEtOAcで抽出し、そして合わせた有機抽出物をブラインで洗浄し、硫酸マグネシウムで乾燥させ、そして濃縮した。残留物をフラッシュクロマトグラフィー(ジクロロメタン)によって精製し、茶色油状物として生成物(1.14g、40%)を得た。
工程4の表題化合物(675mg、2.8mmol)のEtOH溶液(10mL)(10% Pd/C(200mg)を含有する)を、40psiにてParr装置中で18時間かけて水素化した。溶液を珪藻土で濾過し、そして濾液を乾燥状態まで濃縮し、黄色固体(400mg、100%)を残した。
(S)−2−(3−フルオロ−アゼチジン−1−カルボニル)−4−オキソ−ピロリジン−1−カルボン酸tert−ブチルエステル
工程1 ベンズヒドリル−3−フルオロ−アゼチジン塩酸塩
1−ベンズヒドリル(benzyhydryl)−アゼチジン−3−オール(5.0g、20.9mmol)をベンゼン(50mL)に溶解し、溶液を15℃まで冷却し、そして(ジエチルアミノ)三フッ化硫黄(10.1g、62.7mmol)を滴下した。室温にて一晩撹拌した後、飽和重炭酸ナトリウムを添加した。混合物をEtOAcで抽出し、硫酸マグネシウムで乾燥させ、濾過し、そして濃縮した。残留物をクロマトグラフィー(Biotage(R)40S、10% EtOAc/ヘキサン)によって精製した。生成物をEtOAcに溶解し、HCl(15mL、エーテル中2N)で処理し、簡潔に加熱し、そして濃縮した。固体をエーテルで摩砕し、濾過し、そして乾燥させ、表題化合物(2.58g)を得た。MS m/z 242.3(MH+)。
工程1の生成物(2.58g、9.3mmol)のメタノール溶液(30mL)(10% Pd/C(0.38g)を含有する)を30〜50psiにてParr装置中で60時間かけて水素化した。溶液を珪藻土で濾過し、そして濾液を乾燥状態まで濃縮した。固体をMeOH/EtOAcから再結晶化させ、表題化合物(0.62g、60%)を得た。
N−tert−Boc−4−オキソ−L−プロリン(917mg、4mmol)、工程2の表題化合物(446mg、4mmol)およびHATU(1.673g、4.4mmol)を、窒素下、無水塩化メチレン中で混合した。溶液を氷浴中で冷却し、DIEA(1.4mL、8mmol)を添加した。反応混合物をRTまで温め、そして一晩撹拌した。飽和重炭酸ナトリウムを添加し、層を分離し、そして水層を塩化メチレンで抽出した。合わせた有機部分をブラインで洗浄し、そして硫酸マグネシウムで乾燥させた。粗生成物(2.11g)をクロマトグラフィー(Biotage(R)Flash 40S、95:5 EtOAc:MeOH)によって精製し、淡いピンク色の発泡体として表題化合物(1.06g、92%)を得た。MS m/z 287.3(MH+)。
(S)−2−((S)−3−フルオロ−ピロリジン−1−カルボニル)−4−オキソ−ピロリジン−1−カルボン酸tert−ブチルエステル
N−tert−Boc−4−オキソ−L−プロリン(2.29g、10mmol)、(S)−3−フルオロピロリジン塩酸塩(1.38g、11mmol)およびTEA(2.09mL、15mmol)を、窒素下、無水塩化メチレン(30mL)中で混合した。HOBT(2.03g、15mmol)を添加し、そして混合物を氷浴中で0℃に冷却し、EDC(2.10、11mmol)を添加した。反応混合物をRTまで温め、そして一晩撹拌した。混合物を飽和重炭酸ナトリウムおよびブラインで洗浄し、硫酸マグネシウムで乾燥させた。粗物質(3.15g)をヘキサン:EtOAc(2:1)から再結晶化させ、淡黄色針状晶として表題化合物(2.18g、73%)を得た。MS m/z 301.3(MH+)。
(2S,4S)−2−(3.3−ジフルオロ−ピロリジン−1−カルボニル)−4−ピペラジン−1−イル−ピロリジン−1−カルボン酸tert−ブチルエステル
工程1 4−[(3S,5S)−1−tert−ブトキシカルボニル−5−(3,3−ジフルオロ−ピロリジン−1−カルボニル)−ピロリジン−3−イル]− ピペラジン−1−カルボン酸ベンジルエステル
製造1の表題化合物(1.59g、5mmol)および1−(ベンジルオキシカルボニル)ピペラジン(1.21g、5.5mmol)の1,2−ジクロロエタン溶液(20mL)にAcOH(0.3mL、1.05当量)を添加し、次いでトリアセトキシ水素化ホウ素ナトリウム(2.119g、10mmol)を添加した。反応混合物をRTにて4時間撹拌した。飽和重炭酸ナトリウムを添加し、そして生成物を塩化メチレンで抽出した。有機層をブラインで洗浄し、そして硫酸マグネシウムで乾燥させた。エバポレーションの後、粗生成物(2.28g黄色発泡体)を、EtOAcを用いて溶出するフラッシュクロマトグラフィーによって精製し、白色発泡体として表題化合物(1.28g、49%)を得た。MS m/z 523.3(MH+)。
工程1の生成物(1g、1.91mmol)をEtOH(50mL)に溶解し、そして10% Pd/C(1g、1当量w/w)を慎重に添加し、次いで1,4−シクロヘキサジエン(1.81mL、10当量)を添加した。混合物をRTにてしっかりと蓋の付いたフラスコ中で一晩穏やかに撹拌した。反応混合物を珪藻土に通して濾過し、そして濃縮し、黄色の半固体として生成物(758mg、100%)を得た。MS m/z 389.4(MH+)。
(S)−2−(3,3−ジフルオロ−アゼチジン−1−カルボニル)−4−オキソ−ピロリジン−1−カルボン酸tert−ブチルエステル
N−tert−BOC−4−オキソ−L−プロリン(458mg、2mmol)、3,3−ジフルオロアゼチジン塩酸塩(258mg、2mmol)(WO 2000/47582に記載されるように製造した)およびDIPEA(0.35mL、2mmol)を無水塩化メチレン(10mL)中で混合し、そして0℃に冷却した。次いで、HOBT(405mg、3mmol)を一度に添加し、次いでEDC塩酸塩(422mg、2.2mmol)を添加した。得られた混合物をRTまで温め、一晩撹拌した。飽和重炭酸ナトリウムを添加し、有機層を分離し、そして水層を塩化メチレンで抽出した。合わせた有機抽出物を2回ブラインで洗浄し、硫酸マグネシウムで乾燥させ、濾過し、そして濃縮した。粗生成物(570mg)をヘキサン:塩化メチレン(10:1)で摩砕し、濾過し、そして真空オーブン中で乾燥させ、明るいオレンジ粉末として表題生成物(510mg、84%収率)を得た。MS(m/z):305.1(MH+)。
(2S,4S)−4−フルオロ−ピロリジン−2−カルボニトリル塩酸塩
工程1 (2S,4S)−4−フルオロ−ピロリジン−1,2−ジカルボン酸2−tert−ブチルエステル1−(2,5−ジオキソ−ピロリジン−1−イル)エステル
N−tert−BOC−シス−4−フルオロ−L−プロリン(700mg、3mmol)の無水DMF溶液(8mL)に0℃のN−ヒドロキシスクシンイミド(380mg、3.3mmol)を一度に添加し、次いで少量ずつ1,3−ジイソプロピルカルボジイミド(391mg、3.1mmol)を添加した。反応系をRTまで温め、そして一晩撹拌した。混合物を水(100mL)で希釈し、沈殿物を回収し、冷水で洗浄し真空オーブン中で一晩かけて乾燥させた。生成物(1.093g)をさらに精製することなく使用した。MS m/z 331.3(MH+)。
工程1の表題化合物(1.03g、3.12mmol)をRTのジオキサン(12mL)に溶解し、そして溶液を濃水酸化アンモニウム溶液(10mmol)の液滴で処理した。得られた濃厚な溶液をRTにて3時間撹拌し、次いで6N HClでpH4〜5まで酸性化し、そして塩化メチレン(2×)で抽出した。合わせた抽出物を飽和重炭酸ナトリウムおよびブラインで洗浄し、硫酸マグネシウムで乾燥させ、濾過し、そして濃縮し、透明な油状物(562mg、78%収率)を得た。MS m/z 233.3(MH+)。
0℃の工程2の表題化合物(550mg、2.37mmol)および乾燥ピリジン(0.4mL、2当量)の無水塩化メチレン溶液(15mL)に、窒素下、TFAAの塩化メチレン溶液(2mL)を添加した。溶液を0℃にて2時間撹拌し、次いでRTにて1時間撹拌した。反応混合物を飽和重炭酸ナトリウム溶液およびブラインで洗浄し、硫酸マグネシウムで乾燥させ、濾過し、そして濃縮した。残留物をシリカゲルのフラッシュクロマトグラフィーによって精製し、固まった状態の油状物(458mg、90%収率)を得た。MS m/z 215.3(MH+)。
工程3の表題化合物(400mg)を乾燥アセトニトリル(8mL)に溶解し、そして窒素下、ジオキサン中4N HCl(0.5mL)を添加した。得られた溶液をRTにて一晩撹拌し、そして形成された白色沈殿物を濾過し、真空オーブン中で乾燥させ、表題化合物(128mg、46%収率)を得た。MS m/z 115.1(MH+)。さらなる生成物が濾過によって得ることができた。
(2S)−4,4−ジフルオロ−ピロリジン−2−カルボニトリル塩酸塩
工程1 N−tert−BOC−4,4−ジフルオロピロリジン−2−カルボニトリル
0℃のN−tert−BOC−4,4−ジフルオロピロリジン−L−プロリンアミド(250mg、1mmol)および乾燥ピリジン(97μL、1.2当量)の無水塩化メチレン溶液に、TFAA(252mg、1.2当量)の無水塩化メチレン溶液(1mL)を添加した。溶液をRTまで温め、そして36時間撹拌した。反応を飽和塩化アンモニウムを用いてクエンチし、有機層を1N HCl、飽和重炭酸ナトリウムおよびブラインで連続して洗浄し、硫酸マグネシウムで乾燥させ、濾過し、そして濃縮し、白色の半固体(252mg)を得た。MS m/z 233.1(MH+)。
工程1の表題化合物(245mg)を乾燥アセトニトリル(10mL)に溶解し、そして4N HCl(0.5mL)を添加した。得られた溶液をRTにて5時間撹拌し、そして溶媒を除去した。残留物をEtOAc摩砕し、固体を濾過し、次いで高真空下で乾燥させ、白色固体として表題化合物(105、59%収率)を得た。MS m/z 133.2(MH+)。
((2S,4S)−4−(4−(3−(トリフルオロメチル)フェニル)ピペラジン−1−イル)ピロリジン−2−イル)−(3,3−ジフルオロピロリジン−1−イル)−メタノンジヒドロクロリド
工程1 (2S,4S)−2−[(3,3−ジフルオロピロリジン−1−イル)カルボニル]−4−{4−[3−(トリフルオロメチル) フェニル]ピペラジン−1−イル}ピロリジン−1−カルボン酸tert−ブチルエステル
製造1の表題化合物(96mg、0.3mmol)、1−[3−(トリフルオロメチル)フェニル]ピペラジン(70mg、0.3mmol)およびAcOH(18μL、0.3mmol)を無水1,2−ジクロロエタン(8mL)に溶解した。トリアセトキシ水素化ホウ素ナトリウム(127mg、0.6mmol)を添加した。反応系をRTにて3時間撹拌した後、反応系を飽和重炭酸ナトリウムでクエンチし、EtOAcで抽出し、ブラインで洗浄し、硫酸マグネシウムで乾燥させ、濾過し、そして濃縮した。粗物質をクロマトグラフィー(Biotage(R)Flash 40S、95:5ジクロロメタン:MeOH)によって精製し、白色発泡体として表題化合物(126mg、79%)を得た。MS m/z 533(MH+)。
工程1の生成物(120mg、0.225mmol)をジオキサン(5mL)中4N HClで処理した。RTにて2時間後、混合物を乾燥状態まで濃縮し、エーテルで摩砕し、濾過し、そして真空で乾燥させ、白色固体として表題化合物(92mg)を得た。MS m/z 433(MH+)。
(S)−4−オキソ−ピロリジン−1,2−ジカルボン酸1−tert−ブチルエステル(6.6kg、1.0当量)を反応装置に充填し、次いでジクロロメタン(15体積)を添加した。反応混合物を0℃に冷却した。トリエチルアミン(4.82リットル、1.2当量)を30分かけて添加した。トリエチルアミンの添加が終わると、混合物は懸濁液から透明溶液に変化した。混合物を0℃〜5℃で10分間維持した。反応温度を0℃〜5℃に維持しながら、塩化ピバロイル(3.65kg、1.05当量)をゆっくりと添加した。反応混合物はスラリーに戻った。反応混合物を1時間、0℃〜5℃に維持した後、完了についてHPLC(誘導体化するためにジエチルアミンを使用する)でサンプリングした。−10℃〜0℃にて、3,3−ジフルオロピロリジン塩酸塩(4.13kg、1.0当量)を上記の混合物に10分かけて充填した。−10℃〜0℃にて、トリエチルアミン(4.0リットル、1.0当量)を70分かけてゆっくりと導入した。トリエチルアミンの添加が完了すると、混合物を0〜5℃にて1時間撹拌した。反応はHPLCアッセイ(約1%の出発物質)で完了した。反応を0℃〜5℃の水(10体積)でクエンチした。混合物を20℃〜25℃に加熱した。層を分離し、そして有機層を0.5M HCl(5体積)で洗浄した。有機層を再び5% NaHCO3(2体積)と半飽和ブライン溶液(1.64M、3体積)との組合せで洗浄した。有機溶液を低量の撹拌可能な体積(約20リットル)まで大気中で濃縮した。酢酸エチル(12.6体積、82.8リットル)を添加し、溶液を約6体積まで大気中で濃縮した。混合物を60℃〜65℃にて2時間維持し、そして3時間かけて室温まで冷却した。混合物を20℃〜25℃にて8時間維持した。ヘプタン(8体積)を添加し、混合物を最低2時間粒状化した。固体を濾過し、2:1 ヘプタン/酢酸エチル(1体積)でリンスし、そして25℃〜35℃の棚型乾燥機中で最低12時間乾燥させた。収量:7.26kg、79%。HPLC純度:99.7%。部分真空下、65℃〜70℃にて、母液(86リットル)を12リットルまで濃縮した。混合物を60℃〜65℃に冷却した。酢酸エチル(4.0リットル)を15分かけてゆっくりと添加した。混合物を2時間かけて20℃〜25℃に冷却し、そしてその温度で少なくとも2時間維持した。固体を濾過し、そしてヘプタン/酢酸エチル(3:1 v/v、1.7リットル)でリンスした。棚型乾燥機中で12時間、35℃〜45℃にて乾燥させ、生成物(435グラム)を得た。HPLC純度:96.4%。
反応装置にTHF(20体積)、2−ピペラジン−1−イル−ピリミジン(2.17kg、1.05当量)および工程1からの生成物(4.00kg、1.0当量)を充填した。全ての物質が30分かけて溶解するまで、混合物を20℃〜25℃に維持した。酢酸(0.792kg、1.05当量)を添加した。反応混合物が濁ってくるまでの間、混合物を1時間撹拌した。反応混合物を30分間還流させ、次いで系から水の除去が完了したことを示す66.9℃の安定した温度がオーバーヘッドで観察されるまで、60℃〜70℃にて濃縮した。必要な場合に、さらなるTHFを添加した。最後に、反応装置中の全量を試薬(limit reagent)の15体積となるようにTHFを添加した。反応混合物を−3℃〜7℃に冷却し、そしてHPLC(イミンを還元するためにトリアセトキシ水素化ホウ素ナトリウムを使用する)によってイミンの完全な形成についてサンプリングした。−5℃〜15℃にてトリアセトキシ水素化ホウ素ナトリウム(5.33kg、2.0当量)を懸濁液に数滴ずつ添加した。反応混合物を20℃〜25℃に加熱し、そして12時間維持した。反応が99.8%で完了したことを、HPLC結果で確認した。重炭酸ナトリウム水溶液(10% w/w、10体積)を添加した。スラリーを部分真空下30℃〜60℃にて濃縮して、THF(10体積)を除去した。20℃〜25℃に冷却した後、酢酸エチル(10体積)を懸濁液に添加した。有機層を分離し、そして水層をHPLCでチェックした。2%未満の生成物が含まれていた。有機層を、水(5体積)、飽和ブライン溶液(5体積)で洗浄し、部分真空下、45℃〜50℃にて少量(2体積)になるまで濃縮した。スラリーに45℃〜50℃のヘプタン(10体積)を30分かけて添加した。混合物を20℃〜25℃まで冷却し、そして2時間粒状化した。固体を濾過によって回収し、ヘプタン(2体積)でリンスした。棚型乾燥機中で12時間、35℃〜45℃にて乾燥させ、生成物(5.35kg、91.3%)を得た。
水(19リットル、2体積)を反応装置に充填し、次いで工程2の生成物(9.57kg、1.0当量)を充填した。スラリーに20℃〜30℃の濃HCl(水中37wt%、19.1リットル、2体積)を4時間かけてゆっくりと添加した。HCl(12リットル)を添加した後、スラリーを溶液に投入した。添加が完了した後、反応系をHPLCアッセイで完了した。反応混合物を5℃〜15℃まで冷却した。pH10〜pH11にて、撹拌しながら混合物に50% NaOH水溶液をゆっくりと添加した。厳密に中性になるようにpHをpHメーターでモニターした。添加した50% NaOHの全量は、12.45リットルであった。混合物を20℃〜25℃に温め、そして酢酸エチル(それぞれ、115リットル、12体積および57リットル、6体積)で2回抽出した。2回の抽出の後、水層からのサンプルをHPLCによって分析し、そしてその水溶液中に1%の生成物のみを示した。有機層を合わせ、そして硫酸マグネシウム(5kg)で1時間処理した。混合物を濾過した。濾過ケーキを酢酸エチル(10リットル)でリンスした。スペックフリー操作のための0.2ミクロンのインラインフィルターによって、濾液を反応装置に戻した。(以下の操作は、スペックフリー条件下で行った。)部分真空下、50℃〜60℃にて溶液を20リットル(2体積)になるまで濃縮した。混合物を30分かけて20℃〜25℃まで冷却した。室温まで冷却する際、結晶が生じた。混合物を30分間維持した。ヘキサン(20リットル、2体積)を1時間かけてゆっくりと添加した。混合物を2時間粒状化した。固体生成物を濾過によって回収し、そしてヘキサン/酢酸エチル(10リットル、1:1v/v)でリンスした。フィルターを最低2時間窒素と共に乾燥させた。生成物を44℃にて12時間棚型乾燥機中で乾燥させた。収量:5.7kg、75.9%。m.p.156℃。MS m/z 367(MH+)。1H NMR(400 MHz,D2O):δ8.15(d,2H,J=5.0Hz,ピリミジンのCH),6.55(t,1H,J=4.8Hz,ピリミジンのCH),3.87−3.81(dd,1H,プロリンのH2b、回転異性(rotomeric)),3.78−3.50(m,4H,ピロリジドのN−CH2),3.55−3.40(m,4H,ピペラジンのN−CH2),2.97(dd,1H,J=10.2,6.6 Hz,プロリンのH5a),2.85−2.75(m,1H,プロリンのH4b),2.69(dd,1H,J=10.0,9.1Hz,プロリンのH5b),2.55−2.20(m,7H,ピペラジンの重複N−CH2,ピロリジンのCH2およびプロリンのH3b),1.47−1.38(m,1H,プロリンのH3a)。
{(2S,4S)−[4−(4−ピリミジン−2−イル−ピペラジン−1−イル)−ピロリジン−2−イル]}−(3,3,4,4−テトラフルオロ−ピロリジン−1−イル)−メタノンジヒドロクロリド
工程1 (2S,4S)−4−(4−ピリミジン−2−イルピペラジン−1−イル)−2−[(3,3,4,4−テトラフルオロピロリジン−1−イル)カルボニル]ピロリジン−1−カルボン酸tert−ブチルエステル
DIPEA(261mL、1.5mmol)を製造3の表題化合物(114mg、0.3mmol)、HATU(128mg、0.33mmol)および3,3,4,4−テトラフルオロピロリジン塩酸塩(54mg、0.3mmol)のジクロロメタン懸濁液(5mL)に滴下した。一晩撹拌した後、飽和重炭酸ナトリウム溶液を添加し、混合物をジクロロメタンで抽出し、抽出物を硫酸マグネシウムで乾燥させ、そして濃縮した。残留物をクロマトグラフィー(Biotage(R)Flash 40S、EtOAc)によって精製し、表題化合物を得た。MS m/z 503(MH+)。
工程1の生成物のEtOAc/MeOH溶液をジオキサン(約5mL)中4M HClで処理した。18時間後、溶媒を除去し、そして残留物をアセトニトリルに取り上げ、そして濃縮した。固体をヘキサン中に取り上げ、濾過し、そして乾燥させ、表題化合物(50mg、33%、2工程)を得た。MS m/z 403(MH+)。
(2S,3R,4S)−4−(4−(3−(トリフルオロメチル)ピリジン−2−イル)ピペラジン−1−イル)−3−メチルピロリジン−2−イル)(3,3−ジフルオロピロリジン−1−イル)メタノンジヒドロクロリド
工程1
製造1の表題化合物(5.6g、20mmol)を4Åモレキュラーシーブ(7.9g)を含むベンゼン(50mL)に溶解し、そしてピロリジン(2.0mL、24mmol)で処理した。溶液を濾過し、そして乾燥状態まで濃縮し、オレンジ色の発泡体(7.0g、100%収率)を残した。
工程1の生成物(7.0g、20mmol)のアセトニトリル溶液(100mL)を破砕した炭酸カリウム(5.2g、38mmol)に添加し、ヨウ化メチル(1.5mL、24mmol)で処理した。混合物を90℃まで16時間加熱し、RTまで冷却し、そして濃縮した。残留物をクロロホルム(150mL)に取り上げ、そしてAcOH(5mL)および水(45mL)の混合物を添加した。RTにて3時間後、層を分離し、水層をクロロホルム(3×25mL)で抽出し、そして合わせた有機層を飽和重炭酸ナトリウム(2×25mL)およびブラインで洗浄し、そして茶色の油状物まで濃縮した。油状物をエーテル(75mL)に溶解し、濾過し、そして薄茶色の固体になるまで濃縮した(0.97g、16%収率)。
MeOH(1mL)中の工程2の生成物(74mg、0.25mmol)、1−(3−トリフルオロメチル)ピリジン−2−イル−ピペラジン(63mg、0.28mmol)、AcOH(16μL)および酢酸ナトリウム(23mg、0.28mmol)の混合物に、シアノ水素化ホウ素ナトリウム(21mg、0.28mmol)を添加した。混合物をRTにて65時間撹拌し、次いで濃縮した。残留物をEtOAc(20mL)に取り上げ、そして溶液を1N水酸化ナトリウム(2×3mL)およびブライン(5mL)で洗浄し、硫酸マグネシウムで乾燥させ、そして乾燥状態まで濃縮した。残留物を分取用HPLC(Shimadzu、Columbia、MD;30×50cm Waters−Xterra(R)C18カラム−Waters Instrument Co.,Milford,MA;0.1%水酸化アンモニウムを含む15%アセトニトリルの30mL/分勾配、10分間)によって精製し、無色の固体(35.7mg、26%収率)を得た。
ジオキサン(0.5mL)中HCl(4M)を、工程3の生成物(35mg、0.064mmol)のアセトニトリル溶液(1mL)に添加した。16時間後、混合物を乾燥状態まで濃縮し、そして残留物をエーテル(2mL)で摩砕した。表題化合物を固体として得た(32mg、96%収率)。MS m/z 448.4(MH+)。
(2,4−ジフルオロ−フェニル)−(4−[(3S,5S)−5−(3,3−ジフルオロ−ピロリジン−1−カルボニル)−ピロリジン−3−イル)−ピペラジン−1−イル)−メタノンジヒドロクロリド
工程1 (2S,4S)−4−[4−(2,4−ジフルオロ−ベンゾイル)−ピペラジン−1−イル]−2−(3,3−ジフルオロ−ピロリジン−1−カルボニル)−ピロリジン−1−カルボン酸tert−ブチルエステル
製造7の表題化合物(97mg、0.25mmol)、2,4−ジフルオロ安息香酸(40mg、0.25mmol)およびHATU(95mg、0.3mmol)を窒素下、無水塩化メチレン中で混合し、そして氷浴中0℃まで冷却し、DIEA(32mg、45μL、0.3mmol)を添加した。反応混合物をRTまで温め、そして一晩撹拌した。反応系を飽和重炭酸ナトリウムでクエンチし、そして水層を塩化メチレンで抽出した。合わせた有機抽出物をブラインで洗浄し、硫酸マグネシウムで乾燥させた。塩化メチレン:MeOH(95:5)を使用するフラッシュクロマトグラフィーによって粗生成物を精製し、白色粉末として最終生成物(132mg、100%)を得た。MS m/z 529.4(MH+)。
本明細書中上に列挙された哺乳動物の症状の治療または予防における、式(I)の化合物、それらのプロドラッグおよび立体異性体、ならびに化合物、プロドラッグおよび立体異性体の薬学的に受容可能な塩の有用性は、当業者に公知の慣用的なアッセイ(以下に記載されるインビボおよびインビトロアッセイを含む)において実証され得る。このようなアッセイはまた、式(I)の化合物、それらのプロドラッグおよび立体異性体、ならびに化合物、プロドラッグおよび立体異性体の薬学的に受容可能な塩の活性を、他の化合物の活性と比較し得る手段を提供する。
DPP−IV阻害は、Scharpe,et al.,A.Clin.Chem.,2299(1988)およびLodja,Z.Czechoslovak Medicine,181(1988)の方法から改変される以下のアッセイによってインビトロで実証され得る。酵素基質溶液(150μL)を、ポリスチレン96ウェルプレートのマイクロタイターウェルにピペット注入し、そして4℃に維持する。酵素基質溶液は、0.1Mの塩化ナトリウム、0.1%(v/v)Tritonおよび50μU/mL DPP−IV(MP Biomedicals、Livermore、CA;DPP−IV 5mU/mLストック)を含む50mMのTrisアッセイ緩衝液(pH7.3)中の50μMのGly−Pro−4−メトキシ−β−ナフチルアミド塩酸塩を含む。式(I)の化合物(5μL/ウェル)を添加し、式(I)の化合物の最終濃度を、1ウェル当り3μM〜10nMにする。
試薬ブランクとして、4つのウェルから酵素を除去する。3mMのDiprotin A(5μL)(Bachem Bioscience,Inc.;King of Prussia,PA)を正の性質対照として4つのウェルに添加し、100μMの最終Diprotin A濃度を得る。式(I)の任意の化合物に影響することなく、全酵素活性(即ち、負の対照)を測定するために、蒸留水(5μL)を4つのウェルに添加する。
式(I)の化合物を含むDPP−IVインヒビターの血糖低下作用を、経口ブドウ糖負荷試験において4〜6週齢KK/H1Jマウス(Jackson Labs;Bar Harbor,ME)で示し得る。
ラット薬物動態学的実験を行って、国際出願WO 02/14271に一般に開示される構造的に類似した先行技術の化合物と比較して、本発明の化合物についての長期にわたって維持される血漿濃度の改善を実証した。特に、長期にわたる血漿濃度を、(a)(3,3−ジフルオロピロリジン−1−イル)−((2S,4S)−4−(4−(ピリミジン−2−イル)ピペラジン−1−イル)ピロリジン−2−イル)−メタノンのジヒドリクロリド塩(本明細書以下「CPD 113」)(実施例113に記載されるように製造した)および(b)比較のための((2S,4S)−4−(4−(ピリミジン−2−イル)ピペラジン−1−イル)ピロリジン−2−イル)(ピロリジン−1−イル)メタノンのジヒドロクロリド塩(本明細書以下「比較物(comparator)」)(実施例1またはWO02/14271に一般に記載される方法に従って製造し得る)を投与したラットについて測定した。
Claims (14)
- 式(I):
RaおよびRbが独立して、水素、−(C1−C6)アルキル、アリールまたはヘテロアリールであるか、または
RaおよびRbが、それらが結合する窒素原子と一緒になって、4〜6員の複素環式環を形成し、ここで該環は、場合によって、さらに1〜2個の窒素、酸素または硫黄環ヘテロ原子を組み込み;
R2およびR3が、独立して、水素、ハロゲン、−(C1−C6)アルキルまたは−(C3−C8)シクロアルキルであり;
Qが、共有結合、−C(O)−または−SO2−であり;
HETが、場合によって(A)1〜6個のハロゲン原子、−(C1−C6)アルコキシ、シアノ、ハロゲン、ヒドロキシもしくは−NRaRbで場合によって置換されている1〜4個の−(C1−C6)アルキルまたは(B)1〜6個のハロゲン原子、−(C1−C6)アルコキシ、シアノ、ハロゲン、ヒドロキシもしくは−NRaRbで場合によって置換されている−(C1−C6)アリールアルキルで置換されている、ヘテロシクロアルキル環部分であり;
nが0または1であり;
nが0である場合、Xが−CH2−であり、かつYが−CH2−、−CHF−または−CF2−であるか;
またはnが1である場合、Xが−CH2−、−CHF−または−CF2−であり;かつYが−CH2−、−CHF−または−CF2−であるが、但しXおよびYの両方が−CH2−でなく;そして
Zが水素またはシアノである〕
の化合物もしくはそれらのプロドラッグ、または該化合物もしくはプロドラッグの薬学的に受容可能な塩、または該化合物、プロドラッグもしくは塩の溶媒和物。 - R1が、1〜3個のシアノ、ハロゲン、ニトロ、トリフルオロメチル、−(C1−C6)アルキル、−(C1−C6)アルコキシ、−(C3−C6)シクロアルキルまたはフェニルで場合によって独立して置換されている、アリールまたはヘテロアリールであり;
R2が−Hまたは−(C1−C6)アルキルであり;
R3が−Hまたは−(C1−C6)アルキルであり;そして
HETが、アゼチジニル、ピペラジニル、ピペリジニル、ピロリジニル、5,6−ジヒドロ−8H−イミダゾ[1,2−a]ピラジン−7−イル、5,6−ジヒドロ−8H−[1,2,4]トリアゾロ[4,3−a]ピラジン−7−イルまたは7,8−ジヒドロ−5H−ピリド[4,3−a]ピリミジン−6−イルである、
請求項1に記載の化合物。 - R1が、ベンゾイソチアゾリル、ベンゾイソオキサゾリル、イソチアゾリル、イソオキサゾリル、オキサゾロピリジル、ピラジニル、ピリジニル、ピリミジニル、キノリニル、キノキサリニル、チアジアゾリル、トリアジニルまたは1,1−ジオキソ−1H−1,2−ベンゾイソチアゾリルであり;
R2およびR3が−Hであり;
Qが共有結合であり;そして
HETがピペラジニルである、
請求項1に記載の化合物。 - R1がピリジニルまたはピリミジニルである、請求項3に記載の化合物。
- nが1であり、Xが−CF2−であり、かつYが−CH2−である、請求項4に記載の化合物。
- 以下:
((2S,4S)−4−(3−(トリフルオロメチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン−7(8H)−イル)ピロリジン−2−イル)−(3,3−ジフルオロピロリジン−1−イル)−メタノン、
(3,3−ジフルオロピロリジン−1−イル)−((2S,4S)−4−(4−(オキサゾロ[5,4−b]ピリジン−2−イル)ピペラジン−1−イル)ピロリジン−2−イル)−メタノン、
(3,3−ジフルオロピロリジン−1−イル)−((2S,4S)−4−(4−(4−メチルピリミジン−2−イル)ピペラジン−1−イル)ピロリジン−2−イル)−メタノン、
((2S,4S)−4−(2−(トリフルオロメチル)−7,8−ジヒドロピリド[4,3−d]ピリミジン−6(5H)−イル)ピロリジン−2−イル)−(3,3−ジフルオロピロリジン−1−イル)−メタノン、
((S)−3−フルオロ−ピロリジン−1−イル)−{(2S,4S)−4−[4−(3−トリフルオロメチル−ピリジン−2−イル)−ピペラジン−1−イル]−ピロリジン−2−イル}−メタノン、
((S)−3−フルオロ−ピロリジン−1−イル)−[(2S,4S)−4−(2−トリフルオロメチル−7,8−ジヒドロ−5H−ピリド[4,3−d]ピリミジン−6−イル)−ピロリジン−2−イル]−メタノン、
(3,3−ジフルオロ−ピロリジン−1−イル)−[(2S,4S)−4−(4−オキサゾロ[4,5−c]ピリジン−2−イル−ピペラジン−1−イル)−ピロリジン−2−イル]−メタノン、
[(2S,4S)−4−(2−シクロプロピル−7,8−ジヒドロ−5H−ピリド[4,3d]ピリミジン−6−イル)−ピロリジン−2−イル]−(3−フルオロ−アゼチジン−1−イル)−メタノン、
(3,3−ジフルオロ−ピロリジン−1−イル)−[(2S,4S)−4−(2−エトキシ−7,8−ジヒドロ−5H−ピリド[4,3−d]ピリミジン−6−イル)−ピロリジン−2−イル]−メタノン、
2−{4−[(3S,5S)−5−(3−フルオロ−アゼチジン−1−カルボニル)−ピロリジン−3−イル]−ピペラジン−1−イル}−ニコチノニトリル、
((S)−3−フルオロ−ピロリジン−1−イル)−[(2S,4S)−4−(4−オキサゾロ[5,4−b]ピリジン−2−イル−ピペラジン−1−イル)−ピロリジン−2−イル]−メタノン、
(3−フルオロ−アゼチジン−1−イル)−[(2S,4S)−4−(2−トリフルオロメチル−7,8−ジヒドロ−5H−ピリド[4,3−d]ピリミジン−6−イル)ピロリジン−2−イル]−メタノン、
2−(4−[(3S,5S)−5−((S)−3−フルオロ−ピロリジン−1−カルボニル)−ピロリジン−3−イル]−ピペラジン−1−イル)−ニコチノニトリル、
(3−フルオロ−アゼチジン−1−イル)−{(2S,4S)−4−[4−(2−トリフルオロメチル−キノリン−4−イル)−ピペラジン−1−イル]−ピロリジン−2−イル}−メタノン、
((3R*,4S*)−3,4−ジフルオロ−ピロリジン−1−イル)−[(2S,4S)−4−(2−トリフルオロメチル−7,8−ジヒドロ−5H−ピリド[4,3−d]ピリミジン−6−イル)−ピロリジン−2−イル]−メタノンおよび
((3R*,4S*)−3,4−ジフルオロ−ピロリジン−1−イル)−[(2S,4S)−4−(4−オキサゾロ[5,4−b]ピリジン−2−イル−ピペラジン−1−イル)−ピロリジン−2−イル]−メタノン;
からなる群から選択される、請求項1に記載の化合物もしくはそれらのプロドラッグ、または該化合物もしくは該プロドラッグの薬学的に受容可能な塩。 - (3,3−ジフルオロピロリジン−1−イル)−((2S,4S)−4−(4−(ピリミジン−2−イル)ピペラジン−1−イル)ピロリジン−2−イル)メタノン、それらのプロドラッグ、またはそれらの薬学的に受容可能な塩、または該プロドラッグの薬学的に受容可能な塩。
- 治療に使用するための、請求項1〜5または7に記載の化合物もしくはそれらのプロドラッグ、該化合物もしくはプロドラッグの薬学的に受容可能な塩、または該化合物、プロドラッグもしくは塩の溶媒和物。
- (a)請求項1〜5または7に記載の化合物もしくはそれらのプロドラッグ、該化合物もしくはプロドラッグの薬学的に受容可能な塩、または該化合物、プロドラッグもしくは塩の溶媒和物;および
(b)薬学的に受容可能な担体、ビヒクル、希釈剤または賦形剤
を含有する、医薬組成物。 - 哺乳動物におけるジペプチジルペプチダーゼIVの阻害方法であって、このような治療が必要な該哺乳動物に、治療有効量の請求項1〜5または7に記載の化合物もしくはそれらのプロドラッグ、該化合物もしくはプロドラッグの薬学的に受容可能な塩、または該化合物、プロドラッグもしくは塩の溶媒和物を投与することを包含する、上記方法。
- 哺乳動物におけるジペプチジルペプチダーゼIVによって媒介される症状の治療方法であって、このような治療が必要な該哺乳動物に、治療有効量の請求項1〜5または7に記載の化合物もしくはそれらのプロドラッグ、該化合物もしくはプロドラッグの薬学的に受容可能な塩、または該化合物、プロドラッグもしくは塩の溶媒和物を投与することを包含する、上記方法。
- 治療する症状が、2型糖尿病、1型糖尿病、耐糖能異常、高血糖症、代謝症候群(X症候群および/またはインスリン抵抗症候群)、糖尿、代謝性アシドーシス、関節炎、白内障、糖尿病性神経障害、糖尿病性ネフロパシー、糖尿病性網膜症、糖尿病性心筋症、肥満症、肥満症によって悪化する症状、高血圧症、高脂質血症、アテローム性動脈硬化症、骨粗鬆症、骨減少症、脆弱化、骨損失、骨折、急性冠症候群、成長ホルモン欠損症に起因する小人症、多嚢胞性卵巣症候群に起因する不妊症、不安、うつ病、不眠症、慢性疲労、てんかん、摂食障害、慢性疼痛、アルコール依存症、腸運動に関連する疾患、潰瘍、過敏性腸症候群、炎症性腸症候群;短小腸症候群;および2型糖尿病における疾患の進行の防止である、請求項11に記載の方法。
- 治療する症状が2型糖尿病である、請求項12に記載の方法。
- 糖尿病を治療する方法であって、このような治療が必要な哺乳動物に、治療有効量の請求項1〜5または7に記載の化合物もしくはそれらのプロドラッグ、該化合物もしくはプロドラッグの薬学的に受容可能な塩、または該化合物、プロドラッグもしくは塩の溶媒和物を投与することを包含する、上記方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57030004P | 2004-05-12 | 2004-05-12 | |
US66430505P | 2005-03-21 | 2005-03-21 | |
PCT/IB2005/001194 WO2005116014A1 (en) | 2004-05-12 | 2005-04-29 | Proline derivatives and their use as dipeptidyl peptidase iv inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007537231A true JP2007537231A (ja) | 2007-12-20 |
JP2007537231A5 JP2007537231A5 (ja) | 2008-04-10 |
JP4227660B2 JP4227660B2 (ja) | 2009-02-18 |
Family
ID=34966115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007512552A Expired - Fee Related JP4227660B2 (ja) | 2004-05-12 | 2005-04-29 | ジペプチジルペプチダーゼivインヒビターとしてのプロリン誘導体およびそれらの使用 |
Country Status (37)
Country | Link |
---|---|
US (4) | US7291618B2 (ja) |
EP (2) | EP1753748B1 (ja) |
JP (1) | JP4227660B2 (ja) |
KR (1) | KR100869616B1 (ja) |
AP (1) | AP2320A (ja) |
AR (1) | AR049894A1 (ja) |
AT (1) | ATE437870T1 (ja) |
AU (1) | AU2005247684B2 (ja) |
BR (1) | BRPI0510284A (ja) |
CA (1) | CA2566108C (ja) |
CR (1) | CR8744A (ja) |
CY (1) | CY1109322T1 (ja) |
DE (1) | DE602005015699D1 (ja) |
DK (1) | DK1753748T3 (ja) |
EA (1) | EA011086B9 (ja) |
EC (1) | ECSP066985A (ja) |
ES (1) | ES2327857T3 (ja) |
GE (1) | GEP20084421B (ja) |
HK (1) | HK1106767A1 (ja) |
HR (1) | HRP20090471T1 (ja) |
IL (1) | IL178339A (ja) |
MA (1) | MA28578B1 (ja) |
MX (1) | MXPA06013114A (ja) |
MY (1) | MY139805A (ja) |
NL (1) | NL1029015C2 (ja) |
NO (1) | NO20064400L (ja) |
NZ (1) | NZ550229A (ja) |
PA (1) | PA8632701A1 (ja) |
PE (1) | PE20060316A1 (ja) |
PL (1) | PL1753748T3 (ja) |
PT (1) | PT1753748E (ja) |
RS (1) | RS51106B (ja) |
SI (1) | SI1753748T1 (ja) |
SV (1) | SV2006002110A (ja) |
TW (1) | TWI347322B (ja) |
UY (1) | UY28892A1 (ja) |
WO (1) | WO2005116014A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011521003A (ja) * | 2008-06-03 | 2011-07-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Nafldの治療における使用のためのdpp−iv阻害剤 |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2282386T3 (es) * | 2001-02-24 | 2007-10-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG | Derivados de xantina, su preparacion y su uso como medicamentos. |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
AU2005247684B2 (en) | 2004-05-12 | 2008-10-23 | Pfizer Products Inc. | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
WO2006073167A1 (ja) * | 2005-01-07 | 2006-07-13 | Ono Pharmaceutical Co., Ltd. | ピロリジン誘導体 |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
NZ571761A (en) | 2006-04-12 | 2010-07-30 | Probiodrug Ag | 5-phenylimidazoles |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
CN103951667A (zh) | 2006-05-04 | 2014-07-30 | 勃林格殷格翰国际有限公司 | 多晶型 |
TW200815405A (en) * | 2006-06-09 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
WO2007148185A2 (en) * | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
UY31290A1 (es) * | 2007-08-16 | 2009-03-31 | Composicion farmacéutica que comprende un derivado de pirazol-o-glucosido | |
PE20090938A1 (es) * | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
UA108596C2 (xx) | 2007-11-09 | 2015-05-25 | Інгібітори пептиддеформілази | |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
PE20110297A1 (es) * | 2008-08-15 | 2011-05-26 | Boehringer Ingelheim Int | Inhibidores de dpp-4 para la cicatrizacion de heridas |
AU2009290911A1 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
EP2379564A1 (en) | 2008-12-19 | 2011-10-26 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
US8865729B2 (en) | 2008-12-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Salt forms of a xanthine compound |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
PT2395983T (pt) | 2009-02-13 | 2020-07-03 | Boehringer Ingelheim Int | Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dp-iv e opcionalmente um agente antidiabético adicional e suas utilizações |
KR20160143897A (ko) | 2009-02-13 | 2016-12-14 | 베링거 인겔하임 인터내셔날 게엠베하 | Dpp-4 억제제(리나글립틴)을 임의로 다른 당뇨병 치료제와 병용하여 포함하는 당뇨병 치료 약제 |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
CA2772488C (en) | 2009-09-11 | 2018-04-17 | Probiodrug Ag | Heterocyclic derivatives as inhibitors of glutaminyl cyclase |
AU2010323068B2 (en) | 2009-11-27 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
EP2545047B9 (en) | 2010-03-10 | 2015-06-10 | Probiodrug AG | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
AU2011228699B2 (en) | 2010-03-19 | 2016-05-19 | Pfizer Inc. | 2,3 dihydro-1H-inden-1-yl- 2,7-diazaspiro [3.5] nonane derivatives and their use as antagonists or inverse agonists of the Ghrelin receptor |
MX2012011631A (es) | 2010-04-06 | 2013-01-18 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo. |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
EA033415B1 (ru) | 2010-05-05 | 2019-10-31 | Boehringer Ingelheim Int | Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2 |
BR112012032579B1 (pt) | 2010-06-24 | 2021-05-11 | Boehringer Ingelheim International Gmbh | uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração |
AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
ES2546465T3 (es) | 2010-10-29 | 2015-09-23 | Pfizer Inc | Inhibidores de N1/N2-lactama acetil-CoA carboxilasa |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
ME02312B (me) | 2011-04-22 | 2016-06-20 | Pfizer | DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
JP2014520879A (ja) | 2011-07-15 | 2014-08-25 | ファイザー・インク | Gpr119調節因子 |
NZ618698A (en) | 2011-07-15 | 2015-08-28 | Boehringer Ingelheim Int | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
RU2013157388A (ru) | 2011-07-22 | 2015-08-27 | Пфайзер Инк. | Хинолинильные модуляторы глюкагонового рецептора |
ES2605565T3 (es) | 2011-08-31 | 2017-03-15 | Pfizer Inc | Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EA027324B1 (ru) | 2011-11-11 | 2017-07-31 | Пфайзер Инк. | 2-тиопиримидиноны |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
SG11201405477XA (en) | 2012-04-06 | 2014-11-27 | Pfizer | Diacylglycerol acyltransferase 2 inhibitors |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
EP2852597B1 (en) | 2012-05-04 | 2016-06-08 | Pfizer Inc | Heterocyclic substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of app, bace1 and bace 2. |
JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体 |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
CA2882389A1 (en) | 2012-09-20 | 2014-03-27 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
WO2014091352A1 (en) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
JP6162820B2 (ja) | 2012-12-19 | 2017-07-12 | ファイザー・インク | 炭素環式および複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
EP2956458B1 (en) | 2013-02-13 | 2017-08-09 | Pfizer Inc | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
WO2015019238A1 (en) * | 2013-08-06 | 2015-02-12 | Ranbaxy Laboratories Limited | Process for the preparation of n-protected (5s)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-one |
EP3055300B1 (en) | 2013-10-09 | 2018-03-07 | Pfizer Inc | Antagonists of prostaglandin ep3 receptor |
WO2015128453A1 (en) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Medical use of a dpp-4 inhibitor |
ES2674240T3 (es) | 2014-03-17 | 2018-06-28 | Pfizer Inc. | Inhibidores de diacilglicerol aciltransferasa 2 para su uso en el tratamiento de trastornos metabólicos y relacionados |
WO2015150995A1 (en) | 2014-04-04 | 2015-10-08 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors |
KR20180078347A (ko) | 2014-04-10 | 2018-07-09 | 화이자 인코포레이티드 | 2-아미노-6-메틸-4,4a,5,6-테트라히드로피라노[3,4-d][1,3]티아진-8a(8H)-일-1,3-티아졸-4-일 아미드 |
WO2016092413A1 (en) | 2014-12-10 | 2016-06-16 | Pfizer Inc. | Indole and indazole compounds that activate ampk |
JP2017538769A (ja) | 2014-12-22 | 2017-12-28 | ファイザー・インク | プロスタグランジンep3受容体の拮抗薬 |
MA42035A (fr) | 2015-05-05 | 2018-03-14 | Pfizer | 2-thiopyrimidinones |
JP2018516254A (ja) | 2015-05-29 | 2018-06-21 | ファイザー・インク | バニン1酵素の阻害薬としての新規なヘテロ環化合物 |
KR102426986B1 (ko) | 2015-06-17 | 2022-07-28 | 화이자 인코포레이티드 | 삼환형 화합물 및 포스포다이에스터라제 억제제로서 이의 용도 |
WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
CA2995153A1 (en) | 2015-08-13 | 2017-02-16 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds |
PT3341367T (pt) | 2015-08-27 | 2021-04-19 | Pfizer | Compostos de arilo ou heteroarilo bicíclicos fusionados como moduladores de irak4 |
WO2017037567A1 (en) | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Regulators of frataxin |
EP3353182A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
EP3353174A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors |
BR112018003489A2 (pt) | 2015-09-24 | 2018-09-25 | Pfizer | n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas |
UA121271C2 (uk) | 2015-12-29 | 2020-04-27 | Пфайзер Інк. | Заміщені 3-азабіцикло[3.1.0]гексани як інгібітори кетогексокінази |
MX2018015089A (es) | 2016-06-10 | 2019-05-13 | Boehringer Ingelheim Int | Combinacion de linagliptina y metformina. |
US10906888B2 (en) | 2016-07-14 | 2021-02-02 | Pfizer Inc. | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme |
AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
WO2019133445A1 (en) | 2017-12-28 | 2019-07-04 | Inception Ibd, Inc. | Aminothiazoles as inhibitors of vanin-1 |
MA53496A (fr) | 2018-08-31 | 2021-12-08 | Pfizer | Combinaisons pour le traitement de la stéatohépatite non alcoolique (nash)/maladie du foie gras non alcoolique (nafld) et de maladies associées |
WO2020102575A1 (en) | 2018-11-16 | 2020-05-22 | Inception Ibd, Inc. | Heterocyclic aminothiazoles and uses thereof |
EP3972596A1 (en) | 2019-05-20 | 2022-03-30 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
EP3990452A1 (en) | 2019-06-28 | 2022-05-04 | Pfizer Inc. | 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases |
TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶2 抑制劑 |
JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ |
BR112022024527A2 (pt) | 2020-06-09 | 2022-12-27 | Pfizer | Compostos de espiro como antagonistas do receptor de melanocortina 4 e usos dos mesmos |
WO2023026180A1 (en) | 2021-08-26 | 2023-03-02 | Pfizer Inc. | Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide |
WO2023100061A1 (en) | 2021-12-01 | 2023-06-08 | Pfizer Inc. | 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure |
WO2023105387A1 (en) | 2021-12-06 | 2023-06-15 | Pfizer Inc. | Melanocortin 4 receptor antagonists and uses thereof |
WO2024075051A1 (en) | 2022-10-07 | 2024-04-11 | Pfizer Inc. | Hsd17b13 inhibitors and/or degraders |
WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
WO2024118524A1 (en) | 2022-11-28 | 2024-06-06 | Cerevel Therapeutics, Llc | Azaindole compounds and their use as phosphodiesterase inhibitors |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3170059B2 (ja) | 1992-08-25 | 2001-05-28 | 誠 大塚 | リン酸カルシウム系薬物徐放体及びその製造方法 |
AU2790895A (en) | 1994-06-10 | 1996-01-05 | Universitaire Instelling Antwerpen | Purification of serine protease and synthetic inhibitors thereof |
GB9903119D0 (en) | 1999-02-11 | 1999-04-07 | Merck Sharp & Dohme | Therapeutic agents |
US7169373B2 (en) | 1999-07-14 | 2007-01-30 | Calcitec, Inc. | Tetracalcium phosphate (TTCP) having calcium phosphate whisker on surface and process for preparing the same |
US7270705B2 (en) | 1999-07-14 | 2007-09-18 | Jiin-Huey Chern Lin | Method of increasing working time of tetracalcium phosphate cement paste |
US6960249B2 (en) | 1999-07-14 | 2005-11-01 | Calcitec, Inc. | Tetracalcium phosphate (TTCP) having calcium phosphate whisker on surface |
US7094282B2 (en) | 2000-07-13 | 2006-08-22 | Calcitec, Inc. | Calcium phosphate cement, use and preparation thereof |
US6840995B2 (en) | 1999-07-14 | 2005-01-11 | Calcitec, Inc. | Process for producing fast-setting, bioresorbable calcium phosphate cements |
JP4101053B2 (ja) | 2000-08-10 | 2008-06-11 | 田辺三菱製薬株式会社 | プロリン誘導体及びその医薬用途 |
TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
JP4070951B2 (ja) | 2000-12-07 | 2008-04-02 | ペンタックス株式会社 | 多孔質リン酸カルシウム系セラミックス焼結体の製造方法 |
AU2002306823B2 (en) | 2001-03-27 | 2006-05-11 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
JP4357293B2 (ja) | 2001-06-27 | 2009-11-04 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類 |
EP1406873B1 (en) | 2001-06-27 | 2007-09-26 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
US6616742B2 (en) | 2001-08-30 | 2003-09-09 | Cana Lab Corporation | Process for preparing a paste from calcium phosphate cement |
CN100341862C (zh) | 2001-09-14 | 2007-10-10 | 三菱制药株式会社 | 噻唑烷衍生物及其医药用途 |
GB0125445D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
WO2003055418A1 (en) | 2001-12-21 | 2003-07-10 | Lagow Richard J | Calcium phosphate bone replacement materials and methods of use thereof |
AU2002360732A1 (en) | 2001-12-26 | 2003-07-24 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
US6955716B2 (en) | 2002-03-01 | 2005-10-18 | American Dental Association Foundation | Self-hardening calcium phosphate materials with high resistance to fracture, controlled strength histories and tailored macropore formation rates |
US20040137032A1 (en) | 2002-03-15 | 2004-07-15 | Wang Francis W. | Combinations of calcium phosphates, bone growth factors, and pore-forming additives as osteoconductive and osteoinductive composite bone grafts |
JP2004026820A (ja) | 2002-05-09 | 2004-01-29 | Taisho Pharmaceut Co Ltd | ジペプチジルペプチダーゼiv阻害剤 |
AU2003235913A1 (en) | 2002-05-09 | 2003-11-11 | Taisho Pharmaceutical Co., Ltd. | Cyanopyrrolidine derivatives |
US20030216777A1 (en) | 2002-05-16 | 2003-11-20 | Yin-Chun Tien | Method of enhancing healing of interfacial gap between bone and tendon or ligament |
CA2487636A1 (en) | 2002-06-04 | 2003-12-11 | Janice Catherine Parker | Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors |
AU2003233010A1 (en) | 2002-06-04 | 2003-12-19 | Pfizer Products Inc. | Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof |
US6710040B1 (en) | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
WO2004007446A1 (ja) | 2002-07-10 | 2004-01-22 | Yamanouchi Pharmaceutical Co., Ltd. | 新規なアゼチジン誘導体又はその塩 |
DE60300666T2 (de) | 2002-07-11 | 2006-04-27 | Biomet Deutschland Gmbh | Verfahren zur Herstellung poröser Calciumphosphatstückchen und -granulaten aus der Gelatineverarbeitung |
TW200404796A (en) | 2002-08-19 | 2004-04-01 | Ono Pharmaceutical Co | Nitrogen-containing compound |
PL376822A1 (pl) | 2002-11-07 | 2006-01-09 | Merck & Co., Inc. | Pochodne fenyloalaniny jako inhibitory dipeptydylopeptydazy do leczenia lub zapobiegania cukrzycy |
WO2004046106A1 (en) | 2002-11-18 | 2004-06-03 | Pfizer Products Inc. | Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides |
JP2005170792A (ja) * | 2002-11-22 | 2005-06-30 | Mitsubishi Pharma Corp | L−プロリン誘導体およびその医薬としての用途。 |
CA2508487A1 (en) | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004071454A2 (en) | 2003-02-13 | 2004-08-26 | Guilford Pharmaceuticals Inc. | Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv |
US20040180091A1 (en) | 2003-03-13 | 2004-09-16 | Chang-Yi Lin | Carbonated hydroxyapatite-based microspherical composites for biomedical uses |
US7306610B2 (en) | 2003-03-21 | 2007-12-11 | Cana Lab Corporation | Method and device for forming a hardened cement in a bone cavity |
WO2004092128A1 (en) | 2003-04-10 | 2004-10-28 | Smithkline Beecham Corporation | Anhydrous crystalline forms of (2s, 4s)-1-{(2r)-2-amino-3-‘4-methoxybenzyl)sulfonyl!-3-methylbutanoyl}-4-fluoropyrrolindine-2-carbonitrile |
US7332520B2 (en) | 2003-06-06 | 2008-02-19 | Merck & Co., Inc. | Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
AU2004249163A1 (en) | 2003-06-17 | 2004-12-29 | Merck & Co., Inc. | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
JP2006528187A (ja) | 2003-07-21 | 2006-12-14 | スミスクライン ビーチャム コーポレーション | (2S,4S)−4−フルオロ−1−[4−フルオロ−β−(4−フルオロフェニル)−L−フェニルアラニル]−2−ピロリジンカルボニトリルp−トルエンスルホン酸塩及びその無水結晶形態 |
WO2005019168A2 (en) | 2003-08-20 | 2005-03-03 | Pfizer Products Inc. | Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors |
WO2005023762A1 (en) | 2003-09-04 | 2005-03-17 | Abbott Laboratories | Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
US7238683B2 (en) | 2003-11-04 | 2007-07-03 | Merck & Co., Inc. | Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
JP2005139107A (ja) | 2003-11-05 | 2005-06-02 | Taisho Pharmaceut Co Ltd | ジペプチジルペプチダーゼiv阻害剤 |
CA2545185A1 (en) | 2003-11-07 | 2005-05-26 | Calcitec, Inc. | Spinal fusion procedure using an injectable bone substitute |
AU2005247684B2 (en) | 2004-05-12 | 2008-10-23 | Pfizer Products Inc. | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors |
-
2005
- 2005-04-29 AU AU2005247684A patent/AU2005247684B2/en not_active Ceased
- 2005-04-29 ES ES05733750T patent/ES2327857T3/es active Active
- 2005-04-29 MX MXPA06013114A patent/MXPA06013114A/es active IP Right Grant
- 2005-04-29 PT PT05733750T patent/PT1753748E/pt unknown
- 2005-04-29 EP EP05733750A patent/EP1753748B1/en active Active
- 2005-04-29 CA CA2566108A patent/CA2566108C/en not_active Expired - Fee Related
- 2005-04-29 EA EA200601896A patent/EA011086B9/ru active Protection Beyond IP Right Term
- 2005-04-29 EP EP09166645.3A patent/EP2116541B1/en active Active
- 2005-04-29 RS RSP-2009/0401A patent/RS51106B/sr unknown
- 2005-04-29 AP AP2006003770A patent/AP2320A/xx active
- 2005-04-29 AT AT05733750T patent/ATE437870T1/de active
- 2005-04-29 DK DK05733750T patent/DK1753748T3/da active
- 2005-04-29 SI SI200530767T patent/SI1753748T1/sl unknown
- 2005-04-29 GE GEAP20059699A patent/GEP20084421B/en unknown
- 2005-04-29 BR BRPI0510284-7A patent/BRPI0510284A/pt active Search and Examination
- 2005-04-29 JP JP2007512552A patent/JP4227660B2/ja not_active Expired - Fee Related
- 2005-04-29 DE DE602005015699T patent/DE602005015699D1/de active Active
- 2005-04-29 WO PCT/IB2005/001194 patent/WO2005116014A1/en active Application Filing
- 2005-04-29 PL PL05733750T patent/PL1753748T3/pl unknown
- 2005-04-29 NZ NZ550229A patent/NZ550229A/en not_active IP Right Cessation
- 2005-04-29 KR KR1020067023663A patent/KR100869616B1/ko not_active IP Right Cessation
- 2005-05-06 MY MYPI20052038A patent/MY139805A/en unknown
- 2005-05-09 PE PE2005000515A patent/PE20060316A1/es not_active Application Discontinuation
- 2005-05-10 AR ARP050101880A patent/AR049894A1/es not_active Application Discontinuation
- 2005-05-11 TW TW094115224A patent/TWI347322B/zh not_active IP Right Cessation
- 2005-05-11 NL NL1029015A patent/NL1029015C2/nl not_active IP Right Cessation
- 2005-05-11 UY UY28892A patent/UY28892A1/es not_active Application Discontinuation
- 2005-05-11 PA PA20058632701A patent/PA8632701A1/es unknown
- 2005-05-12 SV SV2005002110A patent/SV2006002110A/es unknown
- 2005-05-12 US US11/129,277 patent/US7291618B2/en not_active Expired - Fee Related
- 2005-11-16 US US11/282,057 patent/US20060079498A1/en not_active Abandoned
-
2006
- 2006-09-27 IL IL178339A patent/IL178339A/en not_active IP Right Cessation
- 2006-09-28 NO NO20064400A patent/NO20064400L/no not_active Application Discontinuation
- 2006-11-09 EC EC2006006985A patent/ECSP066985A/es unknown
- 2006-11-09 CR CR8744A patent/CR8744A/es unknown
- 2006-11-10 MA MA29446A patent/MA28578B1/fr unknown
- 2006-12-07 US US11/636,011 patent/US7465732B2/en not_active Expired - Fee Related
-
2007
- 2007-03-07 US US11/682,945 patent/US20070161664A1/en not_active Abandoned
- 2007-11-15 HK HK07112455.6A patent/HK1106767A1/xx not_active IP Right Cessation
-
2009
- 2009-08-20 CY CY20091100886T patent/CY1109322T1/el unknown
- 2009-09-04 HR HR20090471T patent/HRP20090471T1/xx unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011521003A (ja) * | 2008-06-03 | 2011-07-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Nafldの治療における使用のためのdpp−iv阻害剤 |
JP2013166800A (ja) * | 2008-06-03 | 2013-08-29 | Boehringer Ingelheim Internatl Gmbh | Nafldの治療における使用のためのdpp−iv阻害剤 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4227660B2 (ja) | ジペプチジルペプチダーゼivインヒビターとしてのプロリン誘導体およびそれらの使用 | |
US11065231B2 (en) | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | |
CN107011330B (zh) | 布鲁顿酪氨酸激酶抑制剂 | |
US20050234065A1 (en) | Dipeptidyl peptidase-IV inhibitors | |
KR20210077719A (ko) | 유비퀴틴 프로테오좀 경로를 통해 btk를 분해시키기 위한 이작용성 화합물 | |
JP6128449B2 (ja) | キナーゼ阻害剤 | |
KR20190012167A (ko) | 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도 | |
WO2007148185A2 (en) | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors | |
EP1325910A1 (en) | Aliphatic nitrogenous five-membered ring compounds | |
AU2017319430A1 (en) | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | |
US8648074B2 (en) | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers | |
US20080269241A1 (en) | Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s | |
WO2006008644A1 (en) | Antidiabetic compounds | |
CN114174280A (zh) | 可用作壳多糖酶抑制剂的取代的氨基三唑 | |
ZA200608741B (en) | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors | |
US20090118274A1 (en) | Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s | |
WO2024032689A1 (zh) | 基于异吲哚啉取代戊二酰亚胺骨架的化合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080221 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080221 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20080221 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20080321 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080401 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080701 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080708 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081001 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081104 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081128 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111205 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121205 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121205 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131205 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |